印度儿科学会咨询委员会关于儿童COVID-19疫苗接种的立场声明
该立场声明由印度儿科学会免疫实践咨询委员会制定,旨在为儿科医生提供儿童COVID-19疫苗接种的循证指导。委员会通过文献复习和会议讨论形成推荐,支持印度政府将COVID-19疫苗接种计划扩展至2-18岁儿童,高危儿童优先接种,并呼吁学会与政府合作实施接种及接种后监测。
要点
- 印度儿科学会支持印度政府将COVID-19疫苗接种计划扩展至2-18岁儿童。
- 患有高危疾病的儿童可优先接种COVID-19疫苗。
- 印度儿科学会及其成员应与印度政府合作实施接种计划及必要的接种后监测。
- 印度专家委员会已推荐Covaxin(Bharat Biotech)用于2-18岁儿童,待印度药品管理总局最终批准。
适用人群与场景
- 2-18岁儿童
- 患有高危疾病的儿童可优先接种
处置流程与药物剂量
- 印度儿科学会支持印度政府将COVID-19疫苗接种计划扩展至2-18岁儿童。
- 高危儿童可优先接种COVID-19疫苗。
- 印度儿科学会及其成员应与印度政府合作实施接种计划及必要的接种后监测。
研究设计与关键结果
- 制定机构:印度儿科学会免疫实践咨询委员会(ACVIP)。
- 方法:委员会制定关键问题,复习儿童COVID-19流行病学和疾病负担文献、儿童COVID-19疫苗研究及印度儿科学会关于儿童COVID-19疫苗接种的立场,在ACVIP聚焦WhatsApp群组讨论可用数据,并于2021年10月24日召开在线会议详细讨论并定稿。
- 推荐:印度儿科学会支持印度政府将COVID-19疫苗接种计划扩展至2-18岁儿童;高危儿童可优先接种;印度儿科学会及其成员应与印度政府合作实施接种计划及必要的接种后监测。
- 背景:第一波疫情后数据显示部分儿童可患严重COVID-19;儿童多系统炎症综合征(MIS-C)和长期COVID导致显著疾病负担;长期学校关闭和隔离对儿童心理社会健康造成严重破坏;许多国家已对选定COVID-19疫苗在儿童中使用授予紧急使用授权(EUA);印度专家委员会(SEC)已推荐Covaxin(Bharat Biotech)用于2-18岁儿童,并提交印度药品管理总局(DCGI)最终批准。
证据类型、等级与局限
- 证据类型:指南/立场声明。
- 局限:原文未报告局限性。
对床旁实践的改变
- 印度儿科学会支持将COVID-19疫苗接种扩展至2-18岁儿童,儿科医生可据此向家长提供接种建议。
- 高危儿童可优先接种COVID-19疫苗。
- 印度儿科学会及其成员应与印度政府合作实施接种计划及必要的接种后监测。
指南或共识出处
- 印度儿科学会免疫实践咨询委员会(ACVIP)立场声明:Coronavirus Disease 2019 (COVID-19) Vaccination for Children,发表于Indian Pediatr。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
JUSTIFICATION: Data generated after the first wave has revealed that some children with coronavirus 19 (COVID-19) can become seriously ill. Multi-inflammatory syndrome in children (MIS-C) and long COVID cause significant morbidity in children. Prolonged school closures and quarantine have played havoc with the psychosocial health of children. Many countries in the world have issued emergency use authorisation (EUA) of selected Covid-19 vaccines for use in children. In India, a Subject Expert Committee (SEC) has recommended the use of Covaxin (Bharat Biotech) for children from the ages of 2-18 years. The recommendation has been given to the Drugs Controller General of India (DCGI) for final approval.
OBJECTIVE: To provide an evidence-based document to guide the pediatricians on the recommendation to administer COVID vaccines to children, as and when they are available for use.
PROCESS: Formulation of key questions was done by the committee, followed by review of literature on epidemiology and burden of Covid-19 in children, review of the studies on COVID vaccines in children, and the IAP stand on Covid-19 vaccination in children. The available data was discussed in the ACVIP focused WhatsApp group followed by an online meeting on 24 October, 2021, wherein the document was discussed in detail and finalized.
RECOMMENDATIONS: The IAP supports the Government of India's decision to extend the COVID-19 vaccination program to children between 2-18 years of age. Children with high-risk conditions may be immunized on a priority basis. The IAP and its members should be a partner with the Government of India, in the implementation of this program and the surveillance that is necessary following the roll-out.
参考来源
- Kasi SG, Dhir SK, Shah A, et al. Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices. Indian Pediatr. 2021. PMID: 34927603
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。